This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (33)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Bipolar Disorder  • Psychopharmacology  • Randomized Controlled Trial  • Alert me on articles by topic

Arch Gen Psychiatry. 2000;57:490-492.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE 12-MONTH, double-blind, placebo-controlled trial of divalproex and lithium for patients with bipolar I disorder who are recovering from a manic episode, by Bowden et al for the Divalproex/Bipolar Study Group,¹ was an extraordinary undertaking. It may be less important that it did not yield clear evidence for superiority of either drug over placebo than that it stimulates reconsideration of strategies for testing prophylactic therapy for bipolar disorder. Placebo controls have rarely been included in such studies since early testing for long-term effectiveness of lithium,^2-4 and the divalproex study illustrates their continued importance. However, the challenge of enrolling 92 placebo-treated subjects no doubt had a major impact on the conduct of the divalproex study, and may well have determined its unexpectedly low recurrence rate with placebo (36/94 [38%])¹ vs 12-month rates of 50% or higher in previous trials.^3-4

RECRUITMENT INTO PLACEBO-CONTROLLED TRIALS

Use of a placebo-treated group increases the difficulty and potential bias in . . . [Full Text of this Article]

SAMPLING CHALLENGES

TRIAL DESIGN

CONCLUSIONS

RELATED ARTICLE

A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder
Charles L. Bowden, Joseph R. Calabrese, Susan L. McElroy, Laszlo Gyulai, Adel Wassef, Frederick Petty, Harrison G. Pope, Jr, James C.-Y. Chou, Paul E. Keck, Jr, Linda J. Rhodes, Alan C. Swann, Robert M. A. Hirschfeld, Patricia J. Wozniak, and for the Divalproex Maintenance Study Group
Arch Gen Psychiatry. 2000;57(5):481-489.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence
Tohen et al.
Am. J. Psychiatry 2003;160:2099-2107.
ABSTRACT | FULL TEXT  

Older patients are eligible for trial of lithium and valproate
Rendell et al.
BMJ 2003;327:395-396.
FULL TEXT  

A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Manic or Hypomanic Patients With Bipolar I Disorder
Bowden et al.
Arch Gen Psychiatry 2003;60:392-400.
ABSTRACT | FULL TEXT  

Relapse Prevention and Bipolar Disorder: A Focus on Bipolar Depression
Rapaport and Hales
Focus 2003;1:15-31.
ABSTRACT | FULL TEXT  

Bibliography for Bipolar Disorder
Focus 2003;1:32-33.
FULL TEXT  

Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Hirschfeld et al.
Focus 2003;1:64-110.
FULL TEXT  

Long-Term Lithium for Bipolar Disorder
BALDESSARINI and TONDO
Am. J. Psychiatry 2001;158:1740-1740.
FULL TEXT  

Developments in mood stabilisers: Depression and public health
Ferrier
Br Med Bull 2001;57:179-192.
ABSTRACT | FULL TEXT  

Divalproex did not differ from placebo or lithium in preventing recurrence of new mood episodes in bipolar I disorder, remission phase
Schneider
Evid. Based Ment. Health 2001;4:9-9.
FULL TEXT  

Is Divalproex an Effective Maintenance Treatment for Mania?
JWatch Psychiatry 2000;2000:2-2.
FULL TEXT